Key result
Recent heart failure care linked to ~4.2-fold higher odds of receiving multi-class GDMT.
Why the study?
Variations in adherence to heart failure with reduced ejection fraction guidelines across hospitals and over time in Taiwan remain unknown.
Does improved adherence to guideline-directed medical therapy over time reduce 1-year mortality in patients with HFrEF?
Cohort (n=3,028)
Yes
Does improved adherence to guideline-directed medical therapy over time reduce 1-year mortality in patients with HFrEF?
Odds Ratio: 4.18
Absolute Event Rate: 86.9% vs 60.4%
p-value: p=<0.001
Temporal improvements in HFrEF guideline adherence across hospitals in Taiwan were associated with a 25% lower risk of 1-year all-cause mortality.
Hypothesis-generating for GDMT optimization in HFrEF; prospective trials needed to confirm mortality benefit.
BACKGROUND: Guideline-directed medical therapy (GDMT) improves outcomes in heart failure with reduced ejection fraction (HFrEF); however, variations in adherence to guidelines across hospitals and over time remain unknown. We used two Taiwanese national registries to investigate temporal and institutional differences in guideline adherence and outcomes among HFrEF patients. METHODS: We looked at two Taiwanese prospective multicenter cohorts, the TSOC-HFrEF (2013-2014) and TSOC HF 2020 (2019-2022) registries. We looked at adherence to Class I recommended diagnostics and GDMT as well as 1-yr mortality rates. Measured covariates and within-hospital clustering were accounted for using multivariable-adjusted generalized estimating equation models and Cox proportional hazards models, which included marginal models. RESULTS: The study included 3,028 patients with HFrEF from 16 medical centers and four regional hospitals. GDMT prescription and diagnostic testing rates increased significantly between the 2013 and 2020 cohorts (≥2 GDMT classes: 60.4% vs. 86.9%; three GDMT classes: 20.6% vs. 51.6%; both p < 0.001). The adjusted odds ratios for prescribing ≥2 and 3 GDMT classes in 2020 versus 2013 were 4.18 and 3.97, respectively, indicating consistent improvements across hospital types (interaction p-values = 0.721 and 0.467). Patients treated at medical centers had significantly higher prescription rates for angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists (39.1% vs. 32.2%, p = 0.011; 62.9% vs. 57.5%, p < 0.001, respectively), while prescription rates for renin-angiotensin system inhibitors were similar across hospital levels (medical center, 71.9% vs. regional hospital, 75.5%, p = 0.179). The 2020 cohort had a significantly lower 1-yr mortality rate (adjusted hazard ratio, 0.75, p = 0.012), with similar survival improvements across medical centers and regional hospitals (interaction, p = 0.106). CONCLUSION: Over time, HFrEF guideline adherence improved significantly at all hospital levels in Taiwan. Improved guideline adherence was associated with a 25% lower risk of all-cause mortality after 1 yr.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=3,028). Treatment in the 2020 cohort (2019-2022) vs. Treatment in the 2013 cohort (2013-2014) was evaluated on Prescription of ≥2 guideline-directed medical therapy (GDMT) classes (OR 4.18, p=<0.001). Treatment in the 2020 cohort compared to the 2013 cohort was associated with higher prescription of ≥2 GDMT classes (86.9% vs 60.4%, OR 4.18) and lower 1-year mortality (HR 0.75, P=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: